Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus ELINEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus ELINEST.
CYCLAFEM 1/35 vs ELINEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
0.5 mg orally once daily.
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal elimination half-life of estradiol (E2) is ~13-16 h, but due to the prodrug nature and accumulation of estrogen metabolites, the effective half-life during continuous use is ~36 h, supporting once-daily dosing.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
~68% renal (50% unchanged, ~18% as inactive metabolites), ~30% biliary/fecal, with enterohepatic recycling of drug and estrogen conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive